Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ).
Sihuan Pharmaceutical Holdings Group Ltd. reported a 20.7% increase in total revenue for the first half of 2025, driven by substantial growth in its medical aesthetics business, which saw an 81.3% rise due to strategic expansions and marketing upgrades. While the generic medicine segment experienced a decline, the innovative medicine sector showed a significant increase, contributing to an overall gross profit margin improvement to 66.1%. The company’s R&D expenses decreased as core projects reached commercial application, indicating a shift towards a more profitable phase.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group Ltd. is a company incorporated in Bermuda, operating in the pharmaceutical industry. It focuses on medical aesthetics, generic medicine, and innovative medicine, with a significant market presence in China.
Average Trading Volume: 116,308,087
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.25B
Find detailed analytics on 0460 stock on TipRanks’ Stock Analysis page.